Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,996,020
  • Shares Outstanding, K 79,845
  • Annual Sales, $ 540,100 K
  • Annual Income, $ -554,130 K
  • 60-Month Beta 1.38
  • Price/Sales 12.66
  • Price/Cash Flow N/A
  • Price/Book 13.25
Trade SRPT with:

Options Overview Details

View History
  • Implied Volatility 56.41%
  • Historical Volatility 36.15%
  • IV Percentile 36%
  • IV Rank 7.54%
  • IV High 175.91% on 01/05/21
  • IV Low 46.67% on 08/18/21
  • Put/Call Vol Ratio 0.18
  • Today's Volume 849
  • Volume Avg (30-Day) 1,199
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 19,733
  • Open Int (30-Day) 12,285

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -2.03
  • Number of Estimates 4
  • High Estimate -1.50
  • Low Estimate -2.33
  • Prior Year -2.50
  • Growth Rate Est. (year over year) +18.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
73.02 +19.99%
on 08/23/21
88.88 -1.42%
on 09/21/21
+12.31 (+16.35%)
since 08/20/21
3-Month
65.30 +34.18%
on 07/27/21
88.88 -1.42%
on 09/21/21
+8.82 (+11.19%)
since 06/21/21
52-Week
65.30 +34.18%
on 07/27/21
181.83 -51.81%
on 12/22/20
-55.22 (-38.66%)
since 09/21/20

Most Recent Stories

More News
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

SRPT : 87.62 (+2.28%)
ABBV : 107.15 (+0.70%)
QURE : 38.22 (+4.37%)
VYGR : 3.01 (+1.35%)
RGNX : 44.23 (+1.49%)
SLDB : 3.20 (+20.30%)
MGTX : 13.18 (+2.33%)
Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the World Muscle Society 2021 Virtual Congress (WMS 2021), taking place Sept. 20-24,...

SRPT : 87.62 (+2.28%)
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced fifteen recipients of Route 79, The Duchenne Scholarship Program. This is the fourth...

SRPT : 87.62 (+2.28%)
Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SRPT : 87.62 (+2.28%)
Sarepta (SRPT) Q2 Earnings Beat, 2021 Sales View Raised

Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in Q2. The company also raises revenues guidance for the year. It plans to start a pivotal study on SRP-9001 next month. Stock up.

RHHBY : 45.9700 (+0.88%)
RGEN : 314.18 (+2.66%)
SRPT : 87.62 (+2.28%)
VNDA : 16.52 (+0.18%)
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 0.97% and 11.29%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

SRPT : 87.62 (+2.28%)
Sarepta Therapeutics: Q2 Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Sarepta Therapeutics Inc. (SRPT) on Wednesday reported a loss of $81.4 million in its second quarter.

SRPT : 87.62 (+2.28%)
Sarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2021.

SRPT : 87.62 (+2.28%)
Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children's Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A

- Limb-girdle muscular dystrophy type 2A is the most common form of LGMD, accounting for a third of LGMD diagnoses

SRPT : 87.62 (+2.28%)
BioNTech (BNTX) to Report Q2 Earnings: What's in the Cards?

On BioNTech's (BNTX) second-quarter earnings call, investors' focus will be on sales number of BNT162b2, its COVID-19 vaccine, developed in partnership with Pfizer.

PFE : 43.92 (-0.63%)
SRPT : 87.62 (+2.28%)
ADVM : 2.25 (+0.45%)
BNTX : 341.35 (+0.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma,...

See More

Key Turning Points

3rd Resistance Point 92.01
2nd Resistance Point 90.45
1st Resistance Point 89.03
Last Price 87.62
1st Support Level 86.05
2nd Support Level 84.49
3rd Support Level 83.07

See More

52-Week High 181.83
Fibonacci 61.8% 137.32
Fibonacci 50% 123.57
Fibonacci 38.2% 109.81
Last Price 87.62
52-Week Low 65.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar